Aardvark Therapeutics Inc
Pharmaceuticals
Aardvark Therapeutics Inc (AARD) Stock News
The latest AARD headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
Pomerantz LLP is investigating potential securities fraud claims against Aardvark Therapeutics following the company's voluntary pause of its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, and a subsequent FDA clinical hold placed on its ARD-101 drug in May 2026. The stock declined 56.2% following the initial announcement and an additional 32.1% after the FDA clinical hold.
- GlobeNewswire Inc.·
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
Aardvark Therapeutics (AARD) stock plummeted 56% on March 2, 2026, after the company paused its Phase 3 HERO trial for ARD-101 due to serious cardiac safety concerns. The abrupt halt contradicts prior investor assurances about the drug's safety profile, prompting Hagens Berman to investigate potential securities law violations and misleading disclosures about the drug's development and FDA communications.